Health Care Related Organization
Roche’s CT-388 Obesity Drug Achieves 22.5% Weight Loss in Phase II, Advances to Phase III
Roche; CT-388; obesity drug; GLP-1/GIP; Phase II; Phase III; weight loss
Sanofi’s Amlitelimab Shows Mixed Phase 3 Results in Eczema Trials, Clouds Blockbuster Hopes but Advances to Regulatory Filings
Sanofi; amlitelimab; Phase 3; eczema; atopic dermatitis; COAST; SHORE; vIGA-AD; EASI-75
Congressional 2026 Spending Bill Advances PBM Reforms in Medicare Part D
PBM reforms; government funding bill; Medicare Part D; pharmacy contracts; 2026 appropriations
Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward
childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule
Pfizer Exits ViiV Healthcare as Shionogi Doubles Stake in $2.13 Billion Deal
Pfizer; Shionogi; ViiV Healthcare; GSK; HIV; stake sale
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
N.Y. Attorney General Sues Former Emergent BioSolutions CEO Robert Kramer for Insider Trading
insider trading; Emergent BioSolutions; Robert Kramer; New York AG; Letitia James; COVID-19 vaccine; AstraZeneca; stock sales
FDA Delays Reviews for Eli Lilly, Sanofi, and Others in New Priority Voucher Program Due to Safety and Efficacy Concerns
FDA delays; Eli Lilly; Sanofi; voucher program; orforglipron; Tzield; safety concerns; efficacy issues
JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense
JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron